GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Decoding the Latest Alzheimer's Setback: Why J&J’s "Failed" Drug Trial is Actually a Hidden Victory for Brain Science
When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association.
Why New Alzheimer’s Treatments are Leaving Atypical Patients Behind
There is a massive blind spot in the current landscape of neurodegenerative care, and it’s one that should keep every health-tech developer awake at night. For decades, the public and medical consciousness has viewed Alzheimer’s disease through a single, narrow lens: the loss of memory. We imagine the grandmother who forgets a name or the father who loses his keys.
Finding Inner Peace: Contemplative Meditation for Alzheimer's Caregivers
Caring for a loved one with Alzheimer's disease can be an emotionally and physically exhausting journey. The constant demands, coupled with the heartbreak of witnessing the gradual decline of a once-familiar person, can take a significant toll on caregivers' well-being.
The Regulatory Shift: Why Diversity Is Now a Technical Requirement
Discover how Glassbury AI’s agentic NLP platform, SYCQ 1.0, solves the FDA Diversity Action Plan (DAP) mandate and accelerates Phase III Alzheimer’s clinical trial matching.
Beyond Clearing Trash: Blocking the IDOL Enzyme Could Revolutionize Alzheimer's Care
Indiana University researchers have discovered that blocking the IDOL enzyme in neurons doesn't just clear toxic Alzheimer's plaques—it also lowers genetic risk (APOE4) and builds cognitive resilience. Read on to learn how this discovery could pave the way for a revolutionary new pill.